Skip to content

Safety and Efficacy of Huaier Granule in Patients with Non-curative Resection for Gastrointestinal Early Carcinoma by Endoscopic Submucosal Dissection: A National Multicenter, Randomized Controlled Trial

Safety and Efficacy of Huaier Granule in Patients with Non-curative Resection for Gastrointestinal Early Carcinoma by Endoscopic Submucosal Dissection: A National Multicenter, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122186
Enrollment
Unknown
Registered
2026-04-09
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Gastrointestinal Cancer

Interventions

Blank Control Group:Routine Follow-up
Huaier Granule Group:Huaier Granules

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Voluntarily participate and sign the informed consent form; 2.Patients with non-curative resection after endoscopic submucosal dissection (ESD) for early gastrointestinal cancer are defined as follows: for gastric lesions, non-piecemeal resection or positive resection margin; differentiated-type intramucosal cancer with an ulcerative lesion >3 cm in size; undifferentiated-type intramucosal cancer without ulceration >2 cm in size; undifferentiated-type intramucosal cancer with ulceration; or presence of submucosal invasion; and for colorectal lesions, positive horizontal margin; or negative vertical margin accompanied by any of the following: poorly differentiated adenocarcinoma, signet-ring cell carcinoma, mucinous adenocarcinoma, depth of submucosal invasion >=1000 µm, positive lymphovascular invasion, or tumor budding grade 2/3. 3.Age >=18 years and <=80 years;

Exclusion criteria

Exclusion criteria: 1.Concomitant severe cardiac, cerebral, pulmonary, hepatic, or renal diseases; 2.Currently receiving immunosuppressive agents or hormone therapy; 3.Women planning pregnancy, pregnant, or breastfeeding; 4.Patients planning to undergo surgery, radiotherapy, or chemotherapy; 5.Other conditions deemed unsuitable for participation by the investigator;

Design outcomes

Primary

MeasureTime frame
3-year Recurrence-Free Survival (RFS);

Secondary

MeasureTime frame
Overall Survival (OS);Adverse Event Rate;Time to Recurrence (TTR);

Countries

China

Contacts

Public ContactLiansong Ye

West China Hospital of Sichuan University

yeliansongnj@wchscu.cn+86 28 85422552

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026